Abstract:Background: Endogenous insulin supplementation is essential for individuals with type 1 diabetes (T1D). However, current treatments, including pancreas transplantation, insulin injections, and oral medications, have significant limitations. The development of engineered cells that can secrete endogenous insulin offers a promising new therapeutic strategy for type 1 diabetes (T1D). This approach could potentially circumvent autoimmune responses associated with the transplantation of differentiated β-cells or systemic delivery of viral vectors. Methods: We utilized CRISPR/Cas9 gene editing coupled with homology-directed repair (HDR) to precisely integrate a promoter-free EMCVIRES-insulin cassette into the 3' untranslated region (UTR) of the GAPDH gene in human HEK-293T cells. Subsequently quantified insulin expression levels in these engineered cells, the viability and functionality of the engineered cells when seeded on different cell vectors (GelMA and Cytopore I) were also assessed. Finally, we investigated the therapeutic potential of EMCVIRES-based insulin secretion circuits in reversing Hyperglycaemia in T1D mice. Result: Our results demonstrate that HDR-mediated gene editing successfully integrated the IRES-insulin loop into the genome of HEK-293T cells, a non-endocrine cell line, enabling the expression of human-derived insulin. Furthermore, Cytopore I microcarriers facilitated cell attachment and proliferation during in vitro culture and enhanced cell survival post-transplantation. Transplantation of these cell-laden microcarriers into mice led to the development of a stable, fat-encapsulated structure. This structure exhibited the expression of the platelet-endothelial cell adhesion molecule CD31, and no significant immune rejection was observed throughout the experiment. Diabetic mice that received the cell carriers reversed hyperglycemia, and blood glucose fluctuations under simulated feeding stimuli were very similar to those of healthy mice. Conclusion: In summary, our study demonstrates that Cytopore I microcarriers are biocompatible and promote long-term cell survival in vivo. The promoter-free EMCVIRES-insulin loop enables non-endocrine cells to secrete mature insulin, leading to a rapid reduction in glucose levels. We have presented a novel promoter-free genetic engineering strategy for insulin secretion and proposed an efficient cell transplantation method. Our findings suggest the potential to expand the range of cell sources available for the treatment of diabetes, offering new avenues for therapeutic interventions.

Stomach-derived human insulin-secreting organoids restore glucose homeostasis

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Generation of insulin-secreting cells from mouse gallbladder stem cells by small molecules in vitro

In vitro derivation of functional insulin-producing cells from human embryonic stem cells

The Reversal of Hyperglycaemia in Diabetic Mice Using Plga Scaffolds Seeded with Islet-Like Cells Derived from Human Embryonic Stem Cells

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

A Novel 3d Liver Organoid System for Elucidation of Hepatic Glucose Metabolism

Evaluation of Islets Derived from Human Fetal Pancreatic Progenitor Cells in Diabetes Treatment

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Generation of Functional Insulin-Producing Cells from Human Embryonic Stem Cells in Vitro

Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia

Insulin-Producing Cells from Human Pancreatic Islet-Derived Progenitor Cells Following Transplantation in Mice

Generation of Human Stem Cell-Derived Pancreatic Organoids (POs) for Regenerative Medicine

Highly Efficient Differentiation of Human ES Cells and Ips Cells into Mature Pancreatic Insulin-Producing Cells

Human Amnion Epithelial Cells Can Be Induced to Differentiate into Functional Insulin-Producing Cells.

Evaluating insulin secretagogues in a humanized mouse model with functional human islets.

Resolving human α versus β cell fate allocation for the generation of stem cell-derived islets

Making human pancreatic islet organoids: Progresses on the cell origins, biomaterials and three-dimensional technologies

Generation of human iPSC-derived pancreatic organoids to study pancreas development and disease

Significant expansion of the donor pool achieved by utilizing islets of variable quality in the production of allogeneic "Neo-Islets", 3-D organoids of Mesenchymal Stromal and islet cells, a novel immune-isolating biotherapy for Type I Diabetes

Human amniotic mesenchymal stem cell-islet organoids enhance the efficiency of islet engraftment in a mouse diabetes model